Lionco Pharmaceutical GroupLtd Balance Sheet Health
Financial Health criteria checks 4/6
Lionco Pharmaceutical GroupLtd has a total shareholder equity of CN¥855.7M and total debt of CN¥259.0M, which brings its debt-to-equity ratio to 30.3%. Its total assets and total liabilities are CN¥1.2B and CN¥349.9M respectively.
Key information
30.3%
Debt to equity ratio
CN¥258.98m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥332.49m |
| Equity | CN¥855.72m |
| Total liabilities | CN¥349.93m |
| Total assets | CN¥1.21b |
Recent financial health updates
Recent updates
Subdued Growth No Barrier To Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) With Shares Advancing 30%
Nov 06
Lionco Pharmaceutical GroupLtd (SHSE:603669) Has Debt But No Earnings; Should You Worry?
Oct 29Lionco Pharmaceutical Group Co.,Ltd. (SHSE:603669) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
May 10There's Reason For Concern Over Lionco Pharmaceutical Group Co.,Ltd.'s (SHSE:603669) Massive 28% Price Jump
Mar 12Financial Position Analysis
Short Term Liabilities: 603669's short term assets (CN¥495.2M) exceed its short term liabilities (CN¥87.7M).
Long Term Liabilities: 603669's short term assets (CN¥495.2M) exceed its long term liabilities (CN¥262.2M).
Debt to Equity History and Analysis
Debt Level: 603669 has more cash than its total debt.
Reducing Debt: 603669's debt to equity ratio has reduced from 35.2% to 30.3% over the past 5 years.
Debt Coverage: 603669's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if 603669's interest payments on its debt are well covered by EBIT.